Advanced search
Publication Cover
Pharmacogenomics and Personalized Medicine Volume 16, 2023 - Issue
Submit an article Journal homepage
254
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Acute Myeloid Leukemia Secondary to Chronic Lymphocytic Leukemia After Prolonged Chlorambucil Therapy: A Case Report

Yan Wu1 Department of Hematology, The Harison International Peace Hospital Affiliated to Hebei Medical University, Hengshui, Hebei, 053000, People’s Republic of China
,
Shan Liu1 Department of Hematology, The Harison International Peace Hospital Affiliated to Hebei Medical University, Hengshui, Hebei, 053000, People’s Republic of China
,
Dongmei Wang1 Department of Hematology, The Harison International Peace Hospital Affiliated to Hebei Medical University, Hengshui, Hebei, 053000, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8027-2644
ORCID Icon &
Xinjie Yao2 Department of Clinical Laboratory, The Harison International Peace Hospital Affiliated to Hebei Medical University, Hengshui, Hebei, 053000, People’s Republic of China
Pages 401-405 | Received 09 Feb 2023, Accepted 21 Apr 2023, Published online: 27 Apr 2023

References

  • Lenartova A, Johannesen TB, Tjønnfjord GE. Chronic lymphocytic leukemia and secondary hematological malignancies: a nation-wide cancer registry study. Eur J Haematol. 2020;104(6):546–553. doi:10.1111/ejh.13396
  • Kumar V, Ailawadhi S, Bojanini L, et al. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019;9(10):75. doi:10.1038/s41408-019-0237-1
  • Benjamini O, Jain P, Trinh L, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma. 2015;56(6):1643–1650. doi:10.3109/10428194.2014.957203
  • DeFilipp Z, Huynh DV, Fazal S, Sahovic E. Allogeneic stem cell transplantation for acute myeloid leukemia with del(7q) following untreated chronic lymphocytic leukemia. Hematol Oncol Stem Cell Ther. 2012;5(3):165–168. doi:10.5144/1658-3876.2012.165
  • Wang L, Lin N. Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: a case report. Medicine. 2021;100(6):e24703. doi:10.1097/MD.0000000000024703
  • Chavez JC, Dalia S, Sandoval-Sus J, et al. Second myeloid malignancies in a large cohort of patients with chronic lymphocytic leukemia: a single institution experience. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S14–S18. doi:10.1016/j.clml.2015.03.013
  • Song Y, Park SY, Wu Z, Liu KH, Seo YH. Hybrid inhibitors of DNA and HDACs remarkably enhance cytotoxicity in leukaemia cells. J Enzyme Inhib Med Chem. 2020;35(1):1069–1079. doi:10.1080/14756366.2020.1754812
  • Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131(25):2761–2772. doi:10.1182/blood-2018-01-791376
  • Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002;20(18):3878–3884. doi:10.1200/JCO.2002.08.128
  • Yamazaki S, Nakamura F, Nannya Y, Nakagawa M, Ichikawa M, Kurokawa M. Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy. Intern Med. 2012;51(24):3427–3430. doi:10.2169/internalmedicine.51.8310
  • Lam CC, Ma ES, Kwong YL. Therapy-related acute myeloid leukemia after single-agent treatment with fludarabine for chronic lymphocytic leukemia. Am J Hematol. 2005;79(4):288–290. doi:10.1002/ajh.20340
  • Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 2010;24(12):2056–2062. doi:10.1038/leu.2010.218
  • Pollyea DA, Pratz KW, Jonas BA, Letai A, Dinardo CD. Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy. Blood. 2018;132(Suppl_1):285. doi:10.1182/blood-2018-99-117179
  • Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120. doi:10.1056/NEJMoa1713976
  • Bogenberger JM, Delman D, Hansen N, et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2015;56(1):226–229. doi:10.3109/10428194.2014.910657
  • Teh TC, Nguyen NY, Moujalled DM, et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia. 2018;32(2):303–312. doi:10.1038/leu.2017.243
  • DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216–228. doi:10.1016/S1470-2045(18)30010-X
  • DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17. doi:10.1182/blood-2018-08-868752

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.